Sana Biotechnology

### Executive Summary Sana Biotechnology raised $981.8M in a Regulation D private placement, first sale on 2025-10-12, in the synthetic biology and intracellular mRNA delivery sector. The massive raise signals strong institutional confidence, with Andreessen Horowitz and Sands Capital listed as related persons. This is a private company with no public ticker. ### Investor Edge Watch for subsequent D/A amendments indicating additional capital or changes in terms, and monitor for any public filings (e.g., S-1) that could signal an upcoming IPO. ### Sector capital positioning This $981.8M raise is one of the largest private placements in synthetic biology and mRNA delivery, indicating a major capital flow into next-generation intracellular therapeutics. ### Convergence Signals No direct public signals (patents, contracts, legislation) are evident from the filing data. However, the involvement of top-tier VCs suggests potential future IPO or strategic partnerships. ### Key Takeaways - Sana Biotechnology raised $981.8M in a private placement, a very large amount for a synthetic biology company. - Andreessen Horowitz and Sands Capital are listed as related persons, indicating top-tier VC backing. - No public ticker exists; this is a private company with no direct public market exposure. ### Risk Indicators & Flags No D/A amendments noted; the amount is unusually large for a Form D, which may indicate a single large investor or a syndicate. Regulatory risks in synthetic biology and mRNA delivery are inherent but not flagged in the filing. ### Verification & References Filing data from SEC EDGAR, accession number 0001702600-24-20407. Verify at https://www.sec.gov/cgi-bin/browse-edgar?company=Sana%20Biotechnology&type=D&action=getcompany. First sale date 2025-10-12, capital raised $981.8M.